ArticleImmunity2024
Mast cells control lung type 2 inflammation via prostaglandin E
Abstract read
In one paragraph
Article in Immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Developments in Mast Cell Research.The Journal of allergy and clinical immunology · 2026Review
- Interleukin-33 and its receptor: multifaceted roles and emerging therapeutic potential.Nature reviews. Immunology · 2026Review
- Mast cells and endothelial cells mediate interleukin-33 and ST2 responses in distal chronic obstructive pulmonary disease lungs.American journal of respiratory and critical care medicine · 2026Article
- WAT-to-BAT communication facilitates the sustained activation of BAT thermogenesis during cold exposure.Cell discovery · 2026Article
- The effects of physical exercise on inflammation-induced maladaptive neuroplasticity in post-traumatic headache.Neuroscience · 2026Review
- Review
- Mast cell-specific CysLT2 receptor signaling inhibits cysteinyl leukotriene-dependent mast cell activation and type 2 allergic lung inflammation.Cell reports · 2026Article
- Constitutively high levels of endogenous soluble ST2 inhibit food allergic responses in mice.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Inter-organ crosstalk in systemic inflammation: a narrative review of molecular mechanisms and pharmacological modulation in the muscle-adipose-liver axis.Frontiers in pharmacology · 2026Review
- The immunology of asthma.Nature immunology · 2025Review
- Transcriptional Regulation of Mouse Mast Cell Differentiation and the Role of Human Lung Mast Cells in Airway Inflammation.Immunological reviews · 2025Review
- Targeting alarmins in asthma: From bench to clinic.The Journal of allergy and clinical immunology · 2025Review
- Update on type 2 immunity.The Journal of allergy and clinical immunology · 2025Review
- Beyond CCR7: dendritic cell migration in type 2 inflammation.Frontiers in immunology · 2025Review
- Low Prostaglandin EJournal of clinical medicine · 2024Review
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Kinan AlhallakDepartments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA; Jeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Jun NagaiDepartments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA; Jeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Kendall ZaleskiJeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Sofia MarshallJeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Tamara SalloumDepartments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA; Jeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Tahereh DerakhshanDepartments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA; Jeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Hiroaki HayashiDepartments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA; Jeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Chunli FengJeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Radomir KratchmarovDepartments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA; Jeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Juying LaiJeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Virinchi KuchibhotlaDepartments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA; Jeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Airi NishidaJeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Barbara BalestrieriDepartments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA; Jeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Tanya LaidlawDepartments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA; Jeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Daniel F DwyerDepartments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA; Jeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Joshua A BoyceDepartments of Medicine and Pediatrics, Harvard Medical School, Boston, MA, USA; Jeff and Penny Vinik Center for Allergic Disease Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: jboyce@rics.bwh.harvard.edu.
Funding
Therapeutic Control of Aspirin-Exacerbated Respiratory DiseaseU19AI095219 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Nora Amanda Barrett · 2011 to 2026
$29.1MIMMUNOLOGIC BASIS OF RESISTANCE AND HYPERSENSITIVITYT32AI007306 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Nora Amanda Barrett, Joshua A Boyce · 1985 to 2026
$12.2MRegulation of Pulmonary Prostaglandins by Leukotriene E4R01AI078908 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BOYCE, JOSHUA A · 2009 to 2025
$8.8MEicosanoid Networks in Aspirin HypersensitivityR01AI136041 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Joshua A Boyce · 2018 to 2026
$5.4MCysLT and P2Y Receptors in Lung InflammationR37AI052353 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BOYCE, JOSHUA A · 2013 to 2022
$5.2MProstaglandin E2-Dependent Control of a Mast Cell IL-33/ST2 Pathway in AsthmaR01AI175149 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Joshua A Boyce · 2023 to 2026
$3.4MOptimizing EP receptor subtype targeting for asthma therapyR01HL136209 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI BIRRELL, MARK A, BOYCE, JOSHUA A · 2017 to 2020
$2.2MEicosanoid Networks in Aspirin Exacerbated Respiratory DiseaseR01HL117945 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BOYCE, JOSHUA A · 2013 to 2016
$1.5MThe inflammatory role of the platelet in aspirin-exacerbated respiratory disease.K23HL111113 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LAIDLAW, TANYA MARIA · 2012 to 2016
$721kNucleotide releasing profiles in allergic inflammatory diseasesR21AI156068 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI NAGAI, JUN · 2021 to 2022
$462kNHLBI NIH HHS K23 HL111113NHLBI NIH HHS R01 HL117945NHLBI NIH HHS R01 HL136209NIAID NIH HHS R01 AI078908NIAID NIH HHS R01 AI136041NIAID NIH HHS R01 AI175149NIAID NIH HHS R21 AI156068NIAID NIH HHS R37 AI052353NIAID NIH HHS T32 AI007306NIAID NIH HHS U19 AI095219
Abstract
Severe asthma and sinus disease are consequences of type 2 inflammation (T2I), mediated by interleukin (IL)-33 signaling through its membrane-bound receptor, ST2. Soluble (s)ST2 reduces available IL-33 and limits T2I, but little is known about its regulation. We demonstrate that prostaglandin E
Indexed as
DinoprostoneInterleukin-1 Receptor-Like 1 ProteinInterleukin-33LungMast CellsMice, KnockoutAnimalsAsthmaFemaleHumansInflammationMaleMiceMice, Inbred C57BLPneumoniaReceptors, Prostaglandin E, EP2 SubtypeDinoprostoneIL1RL1 protein, humanIl1rl1 protein, mouseInterleukin-1 Receptor-Like 1 ProteinInterleukin-33Receptors, Prostaglandin E, EP2 Subtypeaspirin exacerbated respiratory diseaseasthmaIL33mast cellsnasal polypsprostaglandin E(2)ST2type 2 inflammation
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.